NovaBay Pharmaceuticals (NBY) 10-K26 Mar 242023 FY Annual reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2023	Mar. 22, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001389545
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-33678
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0454536
Entity Address, Address Line One	2000 Powell Street, Suite 1150
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NBY
Security Exchange Name	NYSEAMER
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 3,050,485
Entity Common Stock, Shares Outstanding		30,098,150
Auditor Name	WithumSmith+Brown, PC
Auditor Location	San Francisco, California
Auditor Firm ID	100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 3,130	$ 5,362
Accounts receivable, net of allowance for credit losses ($3 and $19 at December 31, 2023 and 2022, respectively)	759	1,973
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($627 and $499 at December 31, 2023 and 2022, respectively)	2,877	3,437
Prepaid expenses and other current assets	388	560
Total current assets	7,154	11,332
Operating lease right-of-use assets	1,296	1,831
Property and equipment, net	87	119
Goodwill	0	348
Other intangible assets, net	0	2,280
Other assets	497	489
TOTAL ASSETS	9,034	16,399
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	1,130	1,080
Accrued liabilities	1,516	2,724
Secured Convertible Notes, net of discounts	1,137	0
Operating lease liability	495	453
Total current liabilities	4,278	4,257
Warrant liability	334	0
Operating lease liabilities-non-current	1,108	1,588
Total liabilities	5,720	5,845
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.01 par value; 150,000 shares authorized, 11,230 and 2,035 shares issued and outstanding at December 31, 2023 and 2022, respectively*	112	20
Additional paid-in capital*	176,101	165,713
Accumulated deficit	(174,849)	(158,152)
Total stockholders’ equity	3,314	10,554
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	9,034	16,399
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	275	570
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	$ 1,675	$ 2,403

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts receivable, allowance for doubtful accounts	$ 3	$ 19
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 627	$ 499
Preferred stock, shares authorized (in shares)	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	11,230,000	2,035,000
Common stock, shares outstanding (in shares)	11,230,000	2,035,000
Series B Preferred Stock [Member]
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	6,000	12,000
Preferred stock, shares outstanding (in shares)	6,000	12,000
Series C Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,000	2,000
Preferred stock, shares outstanding (in shares)	1,000	2,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales:
Total sales, net	$ 14,726	$ 14,404
Cost of goods sold	6,831	6,623
Gross profit	7,895	7,781
Operating expenses
Research and development	68	174
Sales and marketing	6,500	7,798
General and administrative	6,330	7,489
Goodwill, intangible and other asset impairment	2,593	6,737
Total operating expenses	15,491	22,198
Operating loss	(7,596)	(14,417)
Non-cash gain on changes in fair value of warrant liability	272	5,446
Non-cash gain on changes in fair value of embedded derivative liability	40	0
Non-cash gain on changes in fair value of contingent liability	0	561
Non-cash loss on modification of common stock warrants	(292)	(1,922)
Other expense, net	(2,064)	(276)
Net loss	(9,640)	(10,608)
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion prices	7,057	5,657
Net loss attributable to common stockholders	$ (16,697)	$ (16,265)
Net loss per share attributable to common stockholders (basic and diluted)* (in dollars per share)	$ (3.96)	$ (10.1)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted)* (in shares)	4,215	1,610
Product [Member]
Sales:
Total sales, net	$ 14,687	$ 14,374
Product and Service, Other [Member]
Sales:
Total sales, net	$ 39	$ 30

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Employees and Directors [Member] Preferred Stock [Member]	Employees and Directors [Member] Common Stock [Member]	[1]	Employees and Directors [Member] Additional Paid-in Capital [Member]	[1]	Employees and Directors [Member] Retained Earnings [Member]	Employees and Directors [Member]	Director [Member] Preferred Stock [Member]	Director [Member] Common Stock [Member]	[1]	The November 2021 Warrants [Member] Preferred Stock [Member]	The November 2021 Warrants [Member] Common Stock [Member]	[1]	The November 2021 Warrants [Member] Additional Paid-in Capital [Member]	[1]	The November 2021 Warrants [Member] Retained Earnings [Member]	The November 2021 Warrants [Member]	The 2022 Warrant Reprice Transaction [Member] Preferred Stock [Member]	The 2022 Warrant Reprice Transaction [Member] Common Stock [Member]	[1]	The 2022 Warrant Reprice Transaction [Member] Additional Paid-in Capital [Member]	[1]	The 2022 Warrant Reprice Transaction [Member] Retained Earnings [Member]	The 2022 Warrant Reprice Transaction [Member]	The 2023 Private Placement [Member] Preferred Stock [Member]	The 2023 Private Placement [Member] Common Stock [Member]	[1]	The 2023 Private Placement [Member] Additional Paid-in Capital [Member]	[1]	The 2023 Private Placement [Member] Retained Earnings [Member]	The 2023 Private Placement [Member]	May 2023 Warrants [Member] Preferred Stock [Member]	May 2023 Warrants [Member] Common Stock [Member]	[1]	May 2023 Warrants [Member] Additional Paid-in Capital [Member]	[1]	May 2023 Warrants [Member] Retained Earnings [Member]	May 2023 Warrants [Member]	The 2023 Warrant Reprice Transaction [Member] Preferred Stock [Member]	The 2023 Warrant Reprice Transaction [Member] Common Stock [Member]	[1]	The 2023 Warrant Reprice Transaction [Member] Additional Paid-in Capital [Member]	[1]	The 2023 Warrant Reprice Transaction [Member] Retained Earnings [Member]	The 2023 Warrant Reprice Transaction [Member]	Conversion of Series B Preferred Stock to Common Stock [Member] Preferred Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member] Common Stock [Member]	[1]	Conversion of Series B Preferred Stock to Common Stock [Member] Additional Paid-in Capital [Member]	[1]	Conversion of Series B Preferred Stock to Common Stock [Member] Retained Earnings [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Preferred Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Common Stock [Member]	[1]	Conversion of Series C Preferred Stock to Common Stock [Member] Additional Paid-in Capital [Member]	[1]	Conversion of Series C Preferred Stock to Common Stock [Member] Retained Earnings [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]	Series B Preferred Stock [Member] Preferred Stock [Member]	Series B Preferred Stock [Member] Common Stock [Member]	[1]	Series B Preferred Stock [Member] Additional Paid-in Capital [Member]	[1]	Series B Preferred Stock [Member] Retained Earnings [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Common Stock [Member]	[1]	Series C Preferred Stock [Member] Additional Paid-in Capital [Member]	[1]	Series C Preferred Stock [Member] Retained Earnings [Member]	Series C Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	[1]	Additional Paid-in Capital [Member]	[1]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021																																																																										14	1,365
Balance at Dec. 31, 2021																																																																										$ 680	$ 13		$ 151,365		$ (141,887)	$ 10,171
Net loss																																																																										0	0		0		(10,608)	(10,608)
Stock-based compensation expense related to employee and director stock awards	$ 0	$ 0		$ 220		$ 0	$ 220
Vesting of director restricted stock awards (in shares)								0	3
Reclassification of November 2021 Warrants from liability											$ 0	$ 0		$ 7,502		$ 0	$ 7,502																																																									$ 0	$ 0		1,851		0	1,851
Conversion of Preferred Stock to common stock (in shares)																																														(2)	161						(1)	159
Conversions of preferred stock to common stock																																														$ (110)	$ 2		$ 108		$ 0	$ 0	$ (632)	$ 2		$ 630		$ 0	$ 0																					742
Down round feature adjustment related to Series B Preferred Stock																																																												$ 0	$ 0		$ 5,657		$ (5,657)	$ 0
Modification of common stock warrants in connection with 2022 Warrant Reprice Transaction																		$ 0	$ 0		$ 1,922		$ 0	$ 1,922
Issuance of common stock in connection with 2022 Warrant Reprice Transaction, net of offering costs (in shares)																																																																										0	328
Issuance of common stock in connection with 2022 Warrant Reprice Transaction, net of offering costs																																																																										$ 0	$ 3		283		0	286
Reclassification of July 2020 Warrants and November 2021 Warrants to liability in connection with 2022 Warrant Reprice Transaction																																																																										$ 0	$ 0		(3,825)		0	(3,825)
Issuance of Series C Preferred Stock and 2022 Warrants, net of offering costs (in shares)																																																																										3	0
Issuance of Series C Preferred Stock and 2022 Warrants, net of offering costs																																																																										$ 3,035	$ 0		0		0	3,035
Shares issued due to Reverse Stock Split rounding feature (in shares)																																																																										0	19
Balance (in shares) at Dec. 31, 2022																																																																										14	2,035
Balance at Dec. 31, 2022																																																																										$ 2,973	$ 20		165,713		(158,152)	10,554
Net loss																																																																										$ 0	$ 0		0		(9,640)	(9,640)
Stock-based compensation expense related to employee and director stock awards	$ 0	$ 0		$ 291		$ 0	$ 291
Vesting of director restricted stock awards (in shares)								0	5
Conversion of Preferred Stock to common stock (in shares)																																														(6)	6,384						(1)	277
Conversions of preferred stock to common stock																																														$ (295)	$ 64		$ 231		$ 0	$ 0																												1,023
Down round feature adjustment related to Series B Preferred Stock																																																												$ 0	$ 0		$ 6,385		$ (6,385)	$ 0	$ 0	$ 0		$ 672		$ (672)	$ 0
Modification of common stock warrants in connection with 2022 Warrant Reprice Transaction																									$ 0	$ 0		$ 286		$ 0	$ 286
Issuance of common stock in connection with 2022 Warrant Reprice Transaction, net of offering costs																		$ 0	$ 25		$ 76		$ 0	$ 101
Issuance of Series C Preferred Stock and 2022 Warrants, net of offering costs																																																					$ (728)	$ 3		$ 725		$ 0	$ 0
Reclassification of May 2023 Warrants from liability																																$ 0	$ 0		$ 1,360		$ 0	$ 1,360
Reclassification of 2023 Private Placement embedded derivative liability																									$ 0	$ 0		$ 169		$ 0	$ 169
Modification of common stock warrants in connection with 2023 Warrant Reprice Transaction																																							$ 0	$ 0		$ 193		$ 0	$ 193
Issuance of common stock in connection with 2023 Warrant Reprice Transaction, net of offering costs (in shares)																		0	2,529
Balance (in shares) at Dec. 31, 2023																																																																										7	11,230
Balance at Dec. 31, 2023																																																																										$ 1,950	$ 112		$ 176,101		$ (174,849)	$ 3,314

[1]After giving retroactive effect to a 1-for-35 reverse stock split that became effective November 15, 2022.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (9,640)	$ (10,608)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	51	120
Amortization of intangible assets	152	363
Goodwill, intangible and other asset impairment	2,593	6,737
Impairment of property and equipment	2	66
Stock-based compensation expense related to employee and director stock awards	291	220
Non-cash gain on changes in fair value of warrant liability	(272)	(5,446)
Non-cash gain on changes in fair value of embedded derivative liability	(40)	0
Non-cash gain on changes in fair value of contingent liability	0	(561)
Non-cash loss on modification of common stock warrants	292	1,922
Accretion of interest and amortization of debt discounts on convertible notes	1,690	0
Changes in operating assets and liabilities:
Accounts receivable	1,214	(305)
Inventory	560	(217)
Prepaid expenses and other current assets	172	218
Operating lease right-of-use assets	417	(1,420)
Other assets	(17)	(5)
Accounts payable and accrued liabilities	(1,158)	667
Operating lease liabilities	(438)	1,595
Net cash used in operating activities	(4,131)	(6,654)
Investing activities:
Purchases of property and equipment	(19)	(112)
Net cash used in investing activities	(19)	(112)
Financing activities:
Payments on Secured Convertible Notes	(1,474)	0
Cash debt issuance cost	(181)	0
Proceeds from warrant exercises and issuance of December 2023 Warrants, net	565	1,703
Payment on line of credit	0	(105)
Net cash provided by financing activities	1,910	4,633
Net decrease in cash, cash equivalents, and restricted cash	(2,240)	(2,133)
Cash, cash equivalents and restricted cash, beginning of year	5,846	7,979
Cash, cash equivalents and restricted cash, end of year	3,606	5,846
Supplemental disclosure of cash flow information:
Interest paid	326	17
Income taxes paid	359	24
Supplemental disclosure of non-cash information:
Conversions of preferred stock to common stock	1,023	742
Down round feature adjustments related to preferred stock	7,057	5,657
Equity transferred to warrant liabilities	0	3,825
Common stock warrant modification recorded as debt discount	113	0
Warrant liabilities transferred to equity	169	0
Addition of operating lease, right-of-use asset	0	2,039
Series C Preferred Stock [Member]
Financing activities:
Proceeds from issuance of Series C Preferred Stock and November 2022 Warrants, net	0	3,035
Convertible Notes and May 2023 Warrants [Member]
Financing activities:
Proceeds from issuance of Secured Convertible Notes and May 2023 Warrants, net of discounts	3,000	0
Warrant Liability [Member]
Supplemental disclosure of non-cash information:
Warrant liabilities transferred to equity	$ 1,360	$ 9,353

Note 1 - Organization

Note 1 - Organization	12 Months Ended
Note 1 - Organization	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. ORGANIZATION NovaBay Pharmaceuticals, Inc. (the “ Company our we us Through our former subsidiary DERMAdoctor, LLC (“ DERMAdoctor 30 December 31, 2023, March 25, 2024, DERMAdoctor Divestiture November 2021 ( DERMAdoctor Acquisition We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for the cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, Reincorporation 1 2 March 25, 2024, Effective November 15, 2022, 1 Reverse Stock Split Going Concern The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 2024 may may The Company’s long-term liquidity needs will be largely determined by the success of our commercialization efforts. To address the Company’s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: ( 1 2 one 3 4 5 may may 1 3 2023 2023 no not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
Note 2 - Summary of Significant Accounting Policies	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ U.S. GAAP Principles of Consolidation The accompanying consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC. All intercompany balances and transactions have been eliminated in consolidation. Subsequent to December 31, 2023, March 25, 2024, 21, Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may not These estimates are based on management’s best estimates and judgment. Actual results may Cash, Cash Equivalents, and Highly Liquid Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2023 2022, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheets (in thousands): December 31, December 31, 2023 2022 Cash and cash equivalents $ 3,130 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 3,606 $ 5,846 The restricted cash amount included in other assets on the consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the years ended December 31, 2023 2022, For the Years Ended December 31, 2023 2022 Avenova Spray $ 7,805 $ 7,651 DERMAdoctor 3,552 4,155 NeutroPhase 1,377 976 Other products 1,953 1,592 Total product revenue, net 14,687 14,374 Other revenue, net 39 30 Total sales, net $ 14,726 $ 14,404 During the years ended December 31, 2023 2022, December 31, 2023 2022, December 31, 2023, March 25, 2024, 21, As of December 31, 2023 2022, 10% December 31, December 31, Major distribution partner 2023 2022 Chongqing Pioneer Pharma Holdings Limited 32 % 11 % Major U.S. Retailer A 21 % * % Avenova Spray Pharmacy Distributor A 12 % 30 % Major U.S. Retailer B * % 15 % * Less than 10% The Company relies on seven not third may may not may Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3, Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand and $19 thousand as of December 31, 2023 2022, Inventory Inventory is comprised of ( 1 2 3 first first December 31, 2023 2022, Property and Equipment, Net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for 805, Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not Goodwill is evaluated for impairment by first may not Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company acquired DERMAdoctor in November 2021, not December 31, 2023, March 25, 2024, 21, During the fourth 2022 2023, 350 20 35 3C. 0 may not 350 20 35 3C, December 31, 2023 $4.2 December 31, 2023 2022, December 31, 2023 2022 During the fourth 2023 2022, not not December 31, 2023, December 31, 2023 2022, Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor Acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the consolidated statements of operations. The DERMAdoctor Acquisition milestone events consisted of financial targets for calendar years 2022 2023 not zero December 31, 2023 2022. December 31, 2022, Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not In connection with the above-mentioned DERMAdoctor reporting unit impairments, discussed in the goodwill and indefinite-lived intangible assets caption above, the Company determined that all of the DERMAdoctor business definite long-lived intangible assets and property and equipment were also impaired. As such, the Company recorded an impairment charge in the years ended December 31, 2023 2022 December 31, 2023; December 31, 2023 2022, Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may December 31, 2023. December 31, 2023. The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not not The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Common Stock Warrants The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 815 The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, 13, Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. See Note 3, Preferred Stock Terms of the Company’s outstanding Preferred Stock include a Ratchet whereby the applicable conversion price may 14, 820, 1 2 3, Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third third Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for product supply is typically due 30 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from Costco is recognized on a “sell-in” basis when control of the goods is transferred to Costco, which generally occurs upon delivery of the products to Costco. Revenue is recorded net of consideration for discounts and product returns. The Company estimates returns based on historical data which is updated quarterly. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied. Cost of Goods Sold Cost of goods sold includes third third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the consolidated statements of operations. Advertising expenses were $1.1 million and $2.0 million, respectively, for the years ended December 31, 2023 2022. Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs 15, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the years ended December 31, 2023 2022, not The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: As of December 31, 2023 2022 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 22,428,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 4,388,000 357,750 Stock options 124,897 131,954 Stock warrants 7,382,447 2,305,519 34,323,344 4,642,803 Recent Accounting Pronouncements Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“ FASB ASUs not not In June 2016, FASB ASU 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 2016 13 January 1, 2023. January 1, 2023, not In December 2023, 2023 09 ASU 2023 09 740 2023 09 5 2023 09 December 15, 2024. 2023 09 not In November 2023, 2023 07, ASU 2023 07 2023 07 CODM 2023 07 January 1, 2024, January 1, 2025, not

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
Note 3 - Fair Value Measurements	Dec. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The following tables presents the Company’s financial instruments measured at fair value on a recurring basis as of December 31, 2023 2022 Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liability $ 334 $ — $ — $ 334 Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2022 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 484 $ 484 $ — $ — The Company’s cash equivalents and restricted cash held as certificates of deposit are classified within Level 1 The Secured Convertible Notes (see Note 12, 2 2023 May 2023 2023 2023 3. The fair value of the December 2023 2023 2023 3. See Note 13, 3 December 31, 2023 2022. Black Scholes Valuation Models and Assumptions The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the years ended December 31, 2023 2022. 15, Warrant Liabilities Various of the Company’s warrants are subject to stockholder approval upon issuance or amendment and prior to exercise. The warrants are recorded as a liability at fair value upon issuance or amendment and continue to be recorded as a liability at fair value at each reporting date until stockholder approval occurs at which time they are transferred to stockholders’ equity at their fair value on the date of approval. Fair value was determined using a Black Scholes model as outlined below. November 2021 Warrants November 2021 Warrants July 2020, November 2021 & September 2022 Warrants July 2020, November 2021 & September 2022 Warrants May 2023 Warrants Measurement event Reporting date Stockholder approval Amendment and Issuance Stockholder Approval Issuance Date December 31, 2021 January 31. 2022 September 9, 2022 November 10, 2022 May 1, 2023 Total Value 9.6 million 7.5 million 5.2 million 1.9 million 1.6 million Gain not applicable 2.1 million not applicable 3.4 million not applicable Assumptions: Exercise price $ 18.55 $ 18.55 $ 6.30 $ 6.30 1.30 Market price $ 13.18 $ 10.50 $ 6.29 $ 2.80 $ 0.72 (a) Volatility 87 % 91 % 79.6 % 79.5 % 80.1 % Risk-free rate 1.31 % 1.65 % 3.58 - 3.43 % 3.93 - 4.15 % 3.60 - 4.04 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % Term (years) 6.0 6.0 3.4 - 6.0 3.2 – 5.8 2.1 - 5.1 % May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Stockholder Approval Issuance Reporting Date Date June 9, 2023 December 21, 2023 December 31, 2023 Total Value $1.4 million $0.4 million $0.3 million Gain $0.2 million not applicable $56 thousand Assumptions: Exercise price $ 1.30 $ 0.25 $ 0.25 Market price $ 0.68 $ 0.23 $ 0.20 Volatility 77.6 % 79.3 % 79.3 % Risk-free rate 3.92 – 4.59 % 3.88 % 3.85 % Dividend yield 0.0 % 0.0 % 0.0 % Term (years) 2.0 - 5.0 5.5 5.5 (a) Adjusted for the dilutive effect of the 2023 Warrant Modifications Amendments to warrant terms are recorded as a non-cash gain (or loss) on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. Fair value was determined using a Black Scholes model as outlined below. July 2020 & November 2021 Warrants Measurement event Prior to amendment After amendment Date September 9, 2022 September 9, 2022 Total Value $3.3 million $5.2 million Loss not applicable $1.9 million Assumptions: Exercise price $ 18.55 - 57.75 $ 6.30 Market price $ 6.29 $ 6.29 Volatility 79.6 % 79.6 % Risk-free rate 3.43 - 3.58 % 3.43 - 3.58 % Dividend yield 0.0 % 0.0 % Term (years) 0.7 – 5.4 3.4 – 6.0 July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 6.30 $ 1.50 Market price $0.72 (a) $0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 – 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 – 5.6 1.1 – 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 3.92 – 4.62 % 3.92 – 4.62 Dividend yield 0.0 % 0.0 % Term (years) 1.5 – 4.5 1.5 – 4.5 (a) Adjusted for the dilutive effect of the 2023 Preferred Stock Conversion Price Adjustments Terms of the Company’s outstanding Preferred Stock include a Ratchet whereby the applicable conversion price may 14, 820, 1 2 Series B Series B & C Measurement event Prior to amendment After amendment Prior to amendment After amendment Date September 9, 2022 September 9, 2022 April 27, 2023 April 27, 2023 Total value (b) $6.9 million $12.5 million $9.6 million $11.6 million Deemed dividend not applicable $5.7 million not applicable $2.0 million Assumptions: Exercise price $ 14.00 $ 6.30 $ 6.30 $ 1.30 Market price $ 6.29 $ 6.29 $0.72 (a) $0.72 (a) Volatility 79.6 % 79.6 % 80.1 % 80.1 % Risk-free rate 3.64 % 3.64 % 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Term (in years) 1.3 1.3 0.8 0.8 Series B & C Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 (a) Adjusted for the dilutive effect of the 2023 (b) Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. Bifurcatable Derivatives Upon issuance in May 2023, 12, Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 1.30 $ 1.30 Market price $ 0.72 (a) $ 0.75 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7 (a) Adjusted for the dilutive effect of the 2023 (b) Adjusted for probability of occurrence.

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	12 Months Ended
Note 4 - Prepaid Expenses and Other Current Assets	Dec. 31, 2023
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2023 2022 Prepaid dues and subscriptions $ 85 $ 43 Prepaid taxes 83 1 Prepaid inventory 73 211 Prepaid insurance 66 146 Other 81 159 Total prepaid expenses and other current assets $ 388 $ 560

Note 5 - Inventory

Note 5 - Inventory	12 Months Ended
Note 5 - Inventory	Dec. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following (in thousands): December 31, December 31, 2023 2022 Raw materials and supplies $ 1,027 $ 1,273 Finished goods 2,477 2,663 Less: Reserve for excess and obsolete inventory (627 ) (499 ) Total inventory, net $ 2,877 $ 3,437

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
Note 6 - Property and Equipment	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following (in thousands): December 31, December 31, 2023 2022 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 431 412 Leasehold improvements 152 152 Total property and equipment, at cost 760 741 Less: Accumulated depreciation (673 ) (622 ) Total property and equipment, net $ 87 $ 119 Depreciation expense was $51 thousand and $120 thousand for the years ended December 31, 2023 2022, During the year ended December 31, 2022, During the years ended December 31, 2023 2022, 2, December 31, 2023, March 25, 2024, 21,

Note 7 - Goodwill

Note 7 - Goodwill	12 Months Ended
Note 7 - Goodwill	Dec. 31, 2023
Notes to Financial Statements
Goodwill Disclosure [Text Block]	NOTE 7. Goodwill is accounted for in accordance with ASC 350, Intangibles-Goodwill and Other. not may During the fourth 2023 2022, 350 20 35 3C. 0 not 350 20 35 3C, $4.2 December 31, 2023 2022, December 31, 2023. December 31, 2023 2022, 2, December 31, 2023, March 25, 2024, 21, The following table presents details of our goodwill during the years ended December 31, 2023 2022 Amount Balance as of December 31, 2021 $ 4,528 Goodwill impairment 4,180 Balance as of December 31, 2022 $ 348 Goodwill impairment 348 Balance as of December 31, 2023 $ —

Note 8 - Other Intangible Asset

Note 8 - Other Intangible Assets	12 Months Ended
Note 8 - Other Intangible Assets	Dec. 31, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 8. As of December 31, 2023 2022, Balance at December 31, 2023 Accumulated Impairments Gross Amortization to Date Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (2,080 ) $ — Amortizable intangible assets Customer relationships 290 (60 ) (230 ) — Trade secrets / product formulations 2,890 (515 ) (2,375 ) — Total other intangible assets $ 5,260 $ (575 ) $ (4,685 ) $ — Balance at December 31, 2022 Accumulated Impairments Gross Amortization to Date Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships 290 (48 ) (172 ) 70 Trade secrets / product formulations 2,890 (375 ) (1,415 ) 1,100 Total other intangible assets $ 5,260 $ (423 ) $ (2,557 ) $ 2,280 In each of the fourth 2023 2022, December 31, 2023. December 31, 2023 2022, 2, December 31, 2023, March 25, 2024, 21, Amortization expense was $152 thousand and $363 thousand for the years ended December 31, 2023 2022,

Note 9 - Accrued Liabilities

Note 9 - Accrued Liabilities	12 Months Ended
Note 9 - Accrued Liabilities	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 9. Accrued liabilities consisted of the following (in thousands): December 31, December 31, 2023 2022 Contract liabilities (see Note 16) $ 946 $ 1,807 Employee payroll and benefits 341 261 Marketing costs 14 104 Inventory purchases 17 101 Other 198 451 Total accrued liabilities $ 1,516 $ 2,724

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
Note 10 - Commitments and Contingencies	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10. Indemnification Agreements As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not December 31, 2023 2022. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not December 31, 2023 2022. Legal Matters From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one may December 31, 2023 2022, no may not Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. December 31, 2023, October 1, 2019 December 31, 2024, 21, Lease costs for the years ended December 31, 2023 2022 For the Years Ended 2023 2022 Operating lease – expense $ 525 $ 525 Operating lease – included in operating cash flow 543 540 The Company has measured its operating lease liabilities as the present value of minimum least payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows: For the Years Ended 2023 2022 Weighted-average remaining lease term (in years) 3.4 4.3 Weighted-average discount rate 5 % 5 % Future lease payments under non-cancelable leases as of December 31, 2023 2024 $ 557 2025 439 2026 444 2027 290 Total future minimum lease payments 1,730 Less: Imputed interest (127 ) Total $ 1,603 Reported as: Operating lease liability $ 495 Operating lease liability- non-current 1,108 Total $ 1,603

Note 11 - Financing Activities

Note 11 - Financing Activities	12 Months Ended
Note 11 - Financing Activities	Dec. 31, 2023
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 11. See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 12, Secured Convertible Notes ; 13, Common Stock Warrants and 14, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. 2023 Warrant Reprice Transaction In December 2023, 2023 May 2023 May 2023 2023 December 2023 The 2023 December 2023 December 2023 December 31, 2023. The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 December 31, 2023 . 2023 Private Placement In May 2023, 2023 May 2023 The Company received gross proceeds of $3.0 million from the 2023 2023 May 2023 first May 2023 The Company incurred total issuance costs of $0.7 million in conjunction with the 2023 December 31, 2023. 2022 Warrant Reprice Transaction In September 2022, 2022 November 2021 July 2020 2022 November 2021 July 2020 2022 September 2022 The 2022 September 2022 September 2022 The Company incurred total issuance costs of $0.5 million in conjunction with the 2022 December 31, 202 2.

Note 12 - Convertible Notes

Note 12 - Convertible Notes	12 Months Ended
Note 12 - Convertible Notes	Dec. 31, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 12. In May 2023, Secured Convertible Notes 2023 11, November 1, 2024. The Secured Convertible Notes may Conversion Price December 31, 2023, Beginning June 1, 2023, 1/18 th may not December 31, 2023 The Secured Convertible Notes also provide for a redemption equal to up to 20% of the gross proceeds received by the Company from any financing completed while the Secured Convertible Notes are outstanding. In connection with the 2023 14, If any event of default occurs, the outstanding principal amount of the Secured Convertible Notes, plus accrued but unpaid interest, liquidated damages and other amounts owing thereof become immediately due and payable in cash at the holder’s election. After any event of default, the Secured Convertible Notes will also accrue interest at a rate up to 18% per year. The Secured Convertible Notes are secured obligations of the Company including a security interest, a lien upon and a right of set-off against all of the Company’s assets as collateral security. As of December 31, 2023, Upon issuance in May 2023, no 3, The lender’s subsequent financing redemption option and certain events of default also represent embedded call options and the Company’s monthly share redemption option represents an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date. The Company allocated $1.2 million of gross proceeds from the 2023 The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represent discounts for the portion of proceeds allocated to the embedded derivative liability and the May 2023 13, The discounts and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes, assuming that the Secured Convertible Notes will be redeemed for cash of $193 thousand per month beginning in June 2023. December 31, 2023, 173%. December 31, 2023, The Secured Convertible Notes are presented as follows as of December 31, 2023 ( Principal amount $ 1,831 Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants (596 ) Unamortized debt issuance costs (98 ) Total Secured Convertible Notes, net $ 1,137 The Secured Convertible Notes, net, are classified as short term in the Company’s consolidated balance sheets. As of December 31, 2023, 2024 $ 1,831

Note 13 - Common Stock Warrants

Note 13 - Common Stock Warrants	12 Months Ended
Note 13 - Common Stock Warrants	Dec. 31, 2023
Notes to Financial Statements
Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block]	NOTE 13. See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 11, Financing Activities ; and 14, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. December 2023 In December 2023, 2023 December 2023 December 2023 June 21, 2029. Upon issuance, the December 2023 not December 31, 2023. May 2023 In May 2023, 2023 May 2023 ● May 2023 1 June 9, 2028 (“ May 2023 1 ● May 2023 2 June 9, 2025 (“ May 2023 2 In December 2023, 2023 May 2023 May 2023 ● May 2023 1 ● May 2023 2 For the amendment in December 2023, May 2023 November 2022 In November 2022, 2022 November 2022 ● November 2022 1 November 20, 2024 (“ November 2022 1 ● November 2022 2 May 20, 2024 (“ November 2022 2 In May 2023, 2023 November 2022 ● November 2022 1 ● November 2022 2 For the amendment in May 2023, November 2022 September 2022 In September 2022, 2022 September 2022 September 2022 September 11, 2028. In May 2023, 2023 September 2022 For the amendment in May 2023, September 2022 November 2021 In November 2021, November 2021 November 2021 March 9, 2023. In September 2022, 2022 November 2021 September 11, 2028. November 2021 In May 2023, 2023 November 2021 For the amendments in September 2022 May 2023, November 2021 July 2020 In July 2020, July 2020 July 2020 ) January 22, 2026. In September 2022, 2022 July 2020 July 2020 In May 2023, 2023 July 2020 For the amendments in September 2022 May 2023, July 2020 Summary of Common Stock Warrant Activity and Outstanding Activity related to common stock warrants outstanding during the years ended December 31, 2023 2022 Warrants Weighted- Average Exercise Price Outstanding at December 31, 2021 202,333 $ 57.13 Warrants granted 2,431,046 11.70 Warrants exercised (327,860 ) 6.30 Warrants expired — — Outstanding at December 31, 2022 2,305,519 $ 7.70 Warrants granted 7,605,776 0.95 Warrants exercised (2,528,848 ) 0.25 Warrants expired — — Outstanding at December 31, 2023 7,382,447 1.82 Common stock warrants outstanding as of December 31, 2023 Series Exercise Price Expiration Date Warrants 2019 Ladenburg Warrants $ 34.65 August 8, 2024 4,799 July 2020 Warrants $ 57.75 January 22, 2026 59,960 July 2020 Warrants $ 1.50 January 22, 2026 77,145 TLF Warrants $ 23.51 January 15, 2026 429 November 2021 Warrants $ 6.30 September 11, 2028 267,858 November 2021 Warrants $ 1.50 September 11, 2028 535,716 September 2022 Warrants $ 6.30 September 11, 2028 89,286 September 2022 Warrants $ 1.50 September 11, 2028 238,574 November 2022 A-1 Warrants $ 6.30 November 20, 2028 79,366 November 2022 A-1 Warrants $ 1.50 November 20, 2028 436,510 November 2022 A-2 Warrants $ 6.30 May 20, 2024 79,366 November 2022 A-2 Warrants $ 1.50 May 20, 2024 436,510 May 2023 B-1 Warrants $ 0.25 June 9, 2028 1,903,848 May 2023 B-2 Warrants $ 0.25 June 9, 2025 644,232 December 2023 Warrants $ 0.25 June 21, 2029 2,528,848 Outstanding at December 31, 2023 7,382,447 Summary of Common Stock Warrant Liabilities The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, Fair value of warrant liability recognized for November 2021 Warrants as of December 31, 2021 $ 9,558 Decrease in fair value of November 2021 Warrants liability (2,056 ) Reclassification of November 2021 Warrants liability to equity (7,502 ) Fair value of warrant liabilities recognized in connection with the 2022 Warrant Reprice Transaction 5,241 Decrease in fair value of 2022 Warrant Reprice Transaction warrant liabilities (3,390 ) Reclassification of 2022 Warrant Reprice Transaction warrant liabilities to equity (1,851 ) Warrant liabilities as of December 31, 2022 $ — Fair value of warrant liability recognized for May 2023 Warrants 1,576 Decrease in fair value of May 2023 Warrants liability (216 ) Reclassification of May 2023 Warrants liability to equity (1,360 ) Fair value of warrant liability recognized for December 2023 Warrants 390 Decrease in fair value of December 2023 Warrants liability (56 ) Fair value of December 2023 Warrants liability at December 31, 2023 $ 334

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity	12 Months Ended
Note 14 - Stockholders' Equity	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 14. Authorized Share Capital Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may Preferred Stock There were two December 31, 2023 2022 Series B Preferred Stock Series C Preferred Stock Preferred Stock not Ratchet Series B Preferred Stock The Company issued 15,000 shares of Series B Preferred Stock in November 2021 December 31, 2023 2022, December 31, 2023 2022, In accordance with the Ratchet, the Series B conversion price was reduced as follows during the years ended December 31, 2023 2022 2, 3, ● In September 2022, 2022 ● In April 2023, 2023 ● In December 2023, 2023 Subsequent to December 31, 2023, January 29, 2024, no Series C Preferred Stock We issued 3,250 shares of Series C Preferred Stock in November 2022 2022 11, December 31, 2023 2022, December 31, 2023 2022, $6.30, In accordance with the Ratchet, the Series C conversion price was reduced as follows during the years ended December 31, 2023 2022 2, 3, ● In April 2023, 2023 ● In December 2023, 2023 Common Stock See Notes 11, 13, December 31, 2023 2022. Reverse Stock Split Effective November 15, 2022, 1 November 10, 2022. 35 1 not 35 35. 1 35

Note 15 - Equity-based Compensa

Note 15 - Equity-based Compensation	12 Months Ended
Note 15 - Equity-based Compensation	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 15. Equity Compensation Plans In October 2007, 2007 2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2021. In March 2017, 2017 2017 June 2, 2017, NQSOs ISOs 2017 not 2007 2017 first January 1, 2018 January 1, 2027 March 31, 2023, 2017 December 31, 2023, 2017 Under the terms of the 2017 may not not not ten no five 10% four 2007 2017 Summary of Outstanding Equity Awards The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2022, December 31, 2023: (in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2022 132 $ 37.99 7.5 $ 69 Options granted 42 1.67 Restricted stock units granted 5 — Options exercised — — Restricted stock units vested (5 ) — Options forfeited/cancelled (19 ) 62.39 Restricted stock units cancelled (30 ) — Outstanding at December 31, 2023 125 31.15 7.3 1 Vested and expected to vest at December 31, 2023 119 32.40 7.3 1 Vested and exercisable at December 31, 2023 63 56.85 5.7 — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of December 31, 2023 December 31, 2023 2022. As of December 31, 2023, Equity Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the years ended December 31, 2023 2022, The weighted-average assumptions used in determining the value of options were as follows: For the Years Ended December 31, Assumptions 2023 2022 Expected price volatility 154 % 158 % Expected term (in years) 6.66 6.45 Risk-free interest rate 3.57 % 2.36 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.29 $ 9.22 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During each of the years ended December 31, 2023 2022, For the years ended December 31, 2023 2022, Stock-Based Awards to Non-Employees During the year ended December 31, 2023, December 31, 2022, not The Company did not December 31, 2023 2022. For the year ended December 31, 2023, December 31, 2022, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): For the Years Ended December 31, 2023 2022 Research and development $ 21 $ 20 Sales and marketing 96 52 General and administrative 174 148 Total stock-based compensation expense $ 291 $ 220

Note 16 - Distribution Agreemen

Note 16 - Distribution Agreements	12 Months Ended
Note 16 - Distribution Agreements	Dec. 31, 2023
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 16. Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the year ended December 31, 2023 ( Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807 Provision related to sales made in: Current period 716 321 106 1,143 Payments and customer credits issued (1,476 ) (362 ) (166 ) (2,004 ) Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the year ended December 31, 2022 ( Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2021 $ 1,150 $ 83 $ 56 $ 1,289 Provision related to sales made in: Current period 1,865 65 448 2,378 Payments and customer credits issued (1,342 ) (95 ) (423 ) (1,860 ) Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807 Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During each of the years ended December 31, 2023 2022, Under these product distribution arrangements, the Company had a contract liability balance of $0.7 million and $1.6 million as of December 31, 2023 2022, Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the years ended December 31, 2023 2022, DERMAdoctor Branded Products Distribution Agreements DERMAdoctor branded products were sold through distribution arrangements with third December 31, 2023 2022, Under these distribution arrangements, the Company had a contract liability balance of $0.2 million as of each of December 31, 2023 2022. Subsequent to December 31, 2023, March 25, 2024, 21,

Note 17 - Employee Benefit Plan

Note 17 - Employee Benefit Plan	12 Months Ended
Note 17 - Employee Benefit Plan	Dec. 31, 2023
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 17. The Company has a 401 first December 31, 2023 2022,

Note 18 - Income Taxes

Note 18 - Income Taxes	12 Months Ended
Note 18 - Income Taxes	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 18. For the years ended December 31, 2023 2022, For the Years Ended December 31, 2023 2022 United States $ (9,640 ) $ (10,608 ) International — — $ (9,640 ) $ (10,608 ) For the years ended December 31, 2023 2022, For the Years Ended December 31, 2023 2022 Current Federal $ — $ — State — — Other — — Total current tax expense $ — $ — Deferred Federal — — State — — Other — — Total deferred tax expense $ — $ — Income tax provision $ — $ — Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company's deferred taxes as of December 31, 2023 2022 For the Years Ended December 31, 2023 2022 Deferred tax assets: Net operating losses $ 36,943 $ 35,234 Acquisition assets 2,257 — Stock options 665 750 Research and development credits 641 641 Accruals 477 464 Operating lease liabilities 368 472 Property and equipment 28 13 Other deferred tax assets 6 331 Total deferred tax assets 41,385 37,905 Deferred tax liabilities: Operating lease right-of-use assets (337 ) (472 ) Total deferred tax liabilities (337 ) (472 ) Valuation allowance (41,048 ) (37,433 ) Net deferred taxes $ — $ — ASC 740, Income Taxes not”. not The valuation allowance increased by $3.6 million and $1.8 million during the years ended December 31, 2023 2022, Net operating loss and tax credit carryforwards as of December 31, 2023, Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 44,443 Does Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 Beginning in 2024 Net operating losses, state $ 117,375 Beginning in 2028 Tax credits, federal $ 542 Beginning in 2031 Tax credits, state $ 125 Indefinite A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the below years are as follows (in thousands): For the Years Ended December 31, 2023 2022 Unrecognized benefit - beginning of period $ 974 $ 974 Change during the period — — Unrecognized benefit - end of period $ 974 $ 974 The entire amount of the unrecognized tax benefits would not December 31, 2023 2022. not 2019 2022 2018 2022 not The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: For the Years Ended December 31, 2023 2022 Statutory rate 21.0 % 21.0 % State tax 4.5 % 7.9 % Change in valuation allowance (19.5 %) (48.0 %) Warrant/equity expenses (3.7 %) 20.2 % Stock-based compensation expense (1.4 %) (4.2 %) Impairment of assets (0.9 %) — % Other (0.1 %) (0.1 %) Change in value of earnout — % 3.2 % Total 0.0 % 0.0 %

Note 19 - Related Party Transac

Note 19 - Related Party Transactions	12 Months Ended
Note 19 - Related Party Transactions	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 19. The following table summarizes information about the Company’s related party revenue and cost of goods sold (in thousands): For the Years Ended December 31, 2023 2022 Chongqing Pioneer Pharma Holdings Limited: Revenue $ 1,377 $ 976 Cost of goods sold 1,225 954 Related party accounts receivable were $0.2 million as of December 31, 2023 2022.

Note 20 - Segment Reporting

Note 20 - Segment Reporting	12 Months Ended
Note 20 - Segment Reporting	Dec. 31, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 20. The Company’s CODM The Company is managed in two 1 2 December 31, 2023, March 25, 2024, 21, Select financial information for each segment is as follows (in thousands): Year Year Ended Ended December 31, Percentage December 31, Percentage 2023 of Total 2022 of Total Eyecare & Wound Care $ 11,174 76 % $ 10,239 71 % Skincare 3,552 24 % 4,165 29 % Total sales, net $ 14,726 100 % $ 14,404 100 % Eyecare & Wound Care $ 3,650 48 % $ 5,645 39 % Skincare 3,946 52 % 8,772 61 % Total operating loss $ 7,596 100 % $ 14,417 100 %

Note 21 - Subsequent Event

Note 21 - Subsequent Event	12 Months Ended
Note 21 - Subsequent Event	Dec. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 21. On January 29, 2024, 14, no 75% 15,000 On March 14, 2024, New Age Membership Units DERMAdoctor DERMAdoctor Divestiture March 25, 2024. not first 2024 7, 8, December 31, 2023 2022, The closing of the DERMAdoctor Divestiture was subject to certain conditions, which included the Company obtaining the consent of the holders (the “ Secured Parties April 27, 2023 ( Security Agreement Security Agreement Amendment April 27, 2023 ( Subsidiary Guarantee Subsidiary Guarantee Termination On March 24, 2024, First Amendment Subsidiary Guarantee Consent Series D Warrants Unsecured Convertible Notes four 4 $525,000 8 March 25, 2024. On March 24, 2024, 14,

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. OTHER INFORMATION During the three December 31, 2023, none 16 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ U.S. GAAP
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC. All intercompany balances and transactions have been eliminated in consolidation. Subsequent to December 31, 2023, March 25, 2024, 21,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may not These estimates are based on management’s best estimates and judgment. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Highly Liquid Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2023 2022, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheets (in thousands): December 31, December 31, 2023 2022 Cash and cash equivalents $ 3,130 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 3,606 $ 5,846 The restricted cash amount included in other assets on the consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the years ended December 31, 2023 2022, For the Years Ended December 31, 2023 2022 Avenova Spray $ 7,805 $ 7,651 DERMAdoctor 3,552 4,155 NeutroPhase 1,377 976 Other products 1,953 1,592 Total product revenue, net 14,687 14,374 Other revenue, net 39 30 Total sales, net $ 14,726 $ 14,404 During the years ended December 31, 2023 2022, December 31, 2023 2022, December 31, 2023, March 25, 2024, 21, As of December 31, 2023 2022, 10% December 31, December 31, Major distribution partner 2023 2022 Chongqing Pioneer Pharma Holdings Limited 32 % 11 % Major U.S. Retailer A 21 % * % Avenova Spray Pharmacy Distributor A 12 % 30 % Major U.S. Retailer B * % 15 % * Less than 10% The Company relies on seven not third may may not may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3,
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand and $19 thousand as of December 31, 2023 2022,
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 first first December 31, 2023 2022,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, Net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for 805, Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not Goodwill is evaluated for impairment by first may not Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company acquired DERMAdoctor in November 2021, not December 31, 2023, March 25, 2024, 21, During the fourth 2022 2023, 350 20 35 3C. 0 may not 350 20 35 3C, December 31, 2023 $4.2 December 31, 2023 2022, December 31, 2023 2022 During the fourth 2023 2022, not not December 31, 2023, December 31, 2023 2022,
Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block]	Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor Acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the consolidated statements of operations. The DERMAdoctor Acquisition milestone events consisted of financial targets for calendar years 2022 2023 not zero December 31, 2023 2022. December 31, 2022,
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not In connection with the above-mentioned DERMAdoctor reporting unit impairments, discussed in the goodwill and indefinite-lived intangible assets caption above, the Company determined that all of the DERMAdoctor business definite long-lived intangible assets and property and equipment were also impaired. As such, the Company recorded an impairment charge in the years ended December 31, 2023 2022 December 31, 2023; December 31, 2023 2022,
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may December 31, 2023. December 31, 2023. The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not not The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Warrant Liabilities [Policy Text Block]	Common Stock Warrants The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 815 The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, 13, Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. See Note 3,
Preferred Stock [Policy Text Block]	Preferred Stock Terms of the Company’s outstanding Preferred Stock include a Ratchet whereby the applicable conversion price may 14, 820, 1 2 3,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third third Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for product supply is typically due 30 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from Costco is recognized on a “sell-in” basis when control of the goods is transferred to Costco, which generally occurs upon delivery of the products to Costco. Revenue is recorded net of consideration for discounts and product returns. The Company estimates returns based on historical data which is updated quarterly. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied.
Cost of Goods Sold [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities.
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the consolidated statements of operations. Advertising expenses were $1.1 million and $2.0 million, respectively, for the years ended December 31, 2023 2022.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs 15,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the years ended December 31, 2023 2022, not The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: As of December 31, 2023 2022 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 22,428,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 4,388,000 357,750 Stock options 124,897 131,954 Stock warrants 7,382,447 2,305,519 34,323,344 4,642,803
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“ FASB ASUs not not In June 2016, FASB ASU 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 2016 13 January 1, 2023. January 1, 2023, not In December 2023, 2023 09 ASU 2023 09 740 2023 09 5 2023 09 December 15, 2024. 2023 09 not In November 2023, 2023 07, ASU 2023 07 2023 07 CODM 2023 07 January 1, 2024, January 1, 2025, not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	December 31, December 31, 2023 2022 Cash and cash equivalents $ 3,130 $ 5,362 Restricted cash included in other assets 476 484 Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows $ 3,606 $ 5,846
Disaggregation of Revenue [Table Text Block]	For the Years Ended December 31, 2023 2022 Avenova Spray $ 7,805 $ 7,651 DERMAdoctor 3,552 4,155 NeutroPhase 1,377 976 Other products 1,953 1,592 Total product revenue, net 14,687 14,374 Other revenue, net 39 30 Total sales, net $ 14,726 $ 14,404
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	December 31, December 31, Major distribution partner 2023 2022 Chongqing Pioneer Pharma Holdings Limited 32 % 11 % Major U.S. Retailer A 21 % * % Avenova Spray Pharmacy Distributor A 12 % 30 % Major U.S. Retailer B * % 15 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of December 31, 2023 2022 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 22,428,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 4,388,000 357,750 Stock options 124,897 131,954 Stock warrants 7,382,447 2,305,519 34,323,344 4,642,803

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	12 Months Ended
Note 3 - Fair Value Measurements (Tables)	Dec. 31, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liability $ 334 $ — $ — $ 334 Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2022 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 484 $ 484 $ — $ —
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	November 2021 Warrants November 2021 Warrants July 2020, November 2021 & September 2022 Warrants July 2020, November 2021 & September 2022 Warrants May 2023 Warrants Measurement event Reporting date Stockholder approval Amendment and Issuance Stockholder Approval Issuance Date December 31, 2021 January 31. 2022 September 9, 2022 November 10, 2022 May 1, 2023 Total Value 9.6 million 7.5 million 5.2 million 1.9 million 1.6 million Gain not applicable 2.1 million not applicable 3.4 million not applicable Assumptions: Exercise price $ 18.55 $ 18.55 $ 6.30 $ 6.30 1.30 Market price $ 13.18 $ 10.50 $ 6.29 $ 2.80 $ 0.72 (a) Volatility 87 % 91 % 79.6 % 79.5 % 80.1 % Risk-free rate 1.31 % 1.65 % 3.58 - 3.43 % 3.93 - 4.15 % 3.60 - 4.04 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % 0.0 % Term (years) 6.0 6.0 3.4 - 6.0 3.2 – 5.8 2.1 - 5.1 % May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Stockholder Approval Issuance Reporting Date Date June 9, 2023 December 21, 2023 December 31, 2023 Total Value $1.4 million $0.4 million $0.3 million Gain $0.2 million not applicable $56 thousand Assumptions: Exercise price $ 1.30 $ 0.25 $ 0.25 Market price $ 0.68 $ 0.23 $ 0.20 Volatility 77.6 % 79.3 % 79.3 % Risk-free rate 3.92 – 4.59 % 3.88 % 3.85 % Dividend yield 0.0 % 0.0 % 0.0 % Term (years) 2.0 - 5.0 5.5 5.5 July 2020 & November 2021 Warrants Measurement event Prior to amendment After amendment Date September 9, 2022 September 9, 2022 Total Value $3.3 million $5.2 million Loss not applicable $1.9 million Assumptions: Exercise price $ 18.55 - 57.75 $ 6.30 Market price $ 6.29 $ 6.29 Volatility 79.6 % 79.6 % Risk-free rate 3.43 - 3.58 % 3.43 - 3.58 % Dividend yield 0.0 % 0.0 % Term (years) 0.7 – 5.4 3.4 – 6.0 July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 6.30 $ 1.50 Market price $0.72 (a) $0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 – 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 – 5.6 1.1 – 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 3.92 – 4.62 % 3.92 – 4.62 Dividend yield 0.0 % 0.0 % Term (years) 1.5 – 4.5 1.5 – 4.5 Series B Series B & C Measurement event Prior to amendment After amendment Prior to amendment After amendment Date September 9, 2022 September 9, 2022 April 27, 2023 April 27, 2023 Total value (b) $6.9 million $12.5 million $9.6 million $11.6 million Deemed dividend not applicable $5.7 million not applicable $2.0 million Assumptions: Exercise price $ 14.00 $ 6.30 $ 6.30 $ 1.30 Market price $ 6.29 $ 6.29 $0.72 (a) $0.72 (a) Volatility 79.6 % 79.6 % 80.1 % 80.1 % Risk-free rate 3.64 % 3.64 % 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Term (in years) 1.3 1.3 0.8 0.8 Series B & C Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 1.30 $ 1.30 Market price $ 0.72 (a) $ 0.75 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Note 4 - Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2023
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, 2023 2022 Prepaid dues and subscriptions $ 85 $ 43 Prepaid taxes 83 1 Prepaid inventory 73 211 Prepaid insurance 66 146 Other 81 159 Total prepaid expenses and other current assets $ 388 $ 560

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	12 Months Ended
Note 5 - Inventory (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, 2023 2022 Raw materials and supplies $ 1,027 $ 1,273 Finished goods 2,477 2,663 Less: Reserve for excess and obsolete inventory (627 ) (499 ) Total inventory, net $ 2,877 $ 3,437

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	12 Months Ended
Note 6 - Property and Equipment (Tables)	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2023 2022 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 431 412 Leasehold improvements 152 152 Total property and equipment, at cost 760 741 Less: Accumulated depreciation (673 ) (622 ) Total property and equipment, net $ 87 $ 119

Note 7 - Goodwill (Tables)

Note 7 - Goodwill (Tables)	12 Months Ended
Note 7 - Goodwill (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Goodwill [Table Text Block]	Amount Balance as of December 31, 2021 $ 4,528 Goodwill impairment 4,180 Balance as of December 31, 2022 $ 348 Goodwill impairment 348 Balance as of December 31, 2023 $ —

Note 8 - Other Intangible Ass_2

Note 8 - Other Intangible Assets (Tables)	12 Months Ended
Note 8 - Other Intangible Assets (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Balance at December 31, 2023 Accumulated Impairments Gross Amortization to Date Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (2,080 ) $ — Amortizable intangible assets Customer relationships 290 (60 ) (230 ) — Trade secrets / product formulations 2,890 (515 ) (2,375 ) — Total other intangible assets $ 5,260 $ (575 ) $ (4,685 ) $ — Balance at December 31, 2022 Accumulated Impairments Gross Amortization to Date Net Indefinite-lived intangible assets Trade names $ 2,080 $ — $ (970 ) $ 1,110 Amortizable intangible assets Customer relationships 290 (48 ) (172 ) 70 Trade secrets / product formulations 2,890 (375 ) (1,415 ) 1,100 Total other intangible assets $ 5,260 $ (423 ) $ (2,557 ) $ 2,280

Note 9 - Accrued Liabilities (T

Note 9 - Accrued Liabilities (Tables)	12 Months Ended
Note 9 - Accrued Liabilities (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2023 2022 Contract liabilities (see Note 16) $ 946 $ 1,807 Employee payroll and benefits 341 261 Marketing costs 14 104 Inventory purchases 17 101 Other 198 451 Total accrued liabilities $ 1,516 $ 2,724

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Tables)	12 Months Ended
Note 10 - Commitments and Contingencies (Tables)	Dec. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	For the Years Ended 2023 2022 Operating lease – expense $ 525 $ 525 Operating lease – included in operating cash flow 543 540 For the Years Ended 2023 2022 Weighted-average remaining lease term (in years) 3.4 4.3 Weighted-average discount rate 5 % 5 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 557 2025 439 2026 444 2027 290 Total future minimum lease payments 1,730 Less: Imputed interest (127 ) Total $ 1,603 Reported as: Operating lease liability $ 495 Operating lease liability- non-current 1,108 Total $ 1,603

Note 12 - Convertible Notes (Ta

Note 12 - Convertible Notes (Tables)	12 Months Ended
Note 12 - Convertible Notes (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	Principal amount $ 1,831 Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants (596 ) Unamortized debt issuance costs (98 ) Total Secured Convertible Notes, net $ 1,137
Schedule of Maturities of Long-Term Debt [Table Text Block]	2024 $ 1,831

Note 13 - Common Stock Warran_2

Note 13 - Common Stock Warrants (Tables)	12 Months Ended
Note 13 - Common Stock Warrants (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Weighted- Average Exercise Price Outstanding at December 31, 2021 202,333 $ 57.13 Warrants granted 2,431,046 11.70 Warrants exercised (327,860 ) 6.30 Warrants expired — — Outstanding at December 31, 2022 2,305,519 $ 7.70 Warrants granted 7,605,776 0.95 Warrants exercised (2,528,848 ) 0.25 Warrants expired — — Outstanding at December 31, 2023 7,382,447 1.82
Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block]	Series Exercise Price Expiration Date Warrants 2019 Ladenburg Warrants $ 34.65 August 8, 2024 4,799 July 2020 Warrants $ 57.75 January 22, 2026 59,960 July 2020 Warrants $ 1.50 January 22, 2026 77,145 TLF Warrants $ 23.51 January 15, 2026 429 November 2021 Warrants $ 6.30 September 11, 2028 267,858 November 2021 Warrants $ 1.50 September 11, 2028 535,716 September 2022 Warrants $ 6.30 September 11, 2028 89,286 September 2022 Warrants $ 1.50 September 11, 2028 238,574 November 2022 A-1 Warrants $ 6.30 November 20, 2028 79,366 November 2022 A-1 Warrants $ 1.50 November 20, 2028 436,510 November 2022 A-2 Warrants $ 6.30 May 20, 2024 79,366 November 2022 A-2 Warrants $ 1.50 May 20, 2024 436,510 May 2023 B-1 Warrants $ 0.25 June 9, 2028 1,903,848 May 2023 B-2 Warrants $ 0.25 June 9, 2025 644,232 December 2023 Warrants $ 0.25 June 21, 2029 2,528,848 Outstanding at December 31, 2023 7,382,447
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair value of warrant liability recognized for November 2021 Warrants as of December 31, 2021 $ 9,558 Decrease in fair value of November 2021 Warrants liability (2,056 ) Reclassification of November 2021 Warrants liability to equity (7,502 ) Fair value of warrant liabilities recognized in connection with the 2022 Warrant Reprice Transaction 5,241 Decrease in fair value of 2022 Warrant Reprice Transaction warrant liabilities (3,390 ) Reclassification of 2022 Warrant Reprice Transaction warrant liabilities to equity (1,851 ) Warrant liabilities as of December 31, 2022 $ — Fair value of warrant liability recognized for May 2023 Warrants 1,576 Decrease in fair value of May 2023 Warrants liability (216 ) Reclassification of May 2023 Warrants liability to equity (1,360 ) Fair value of warrant liability recognized for December 2023 Warrants 390 Decrease in fair value of December 2023 Warrants liability (56 ) Fair value of December 2023 Warrants liability at December 31, 2023 $ 334

Note 15 - Equity-based Compen_2

Note 15 - Equity-based Compensation (Tables)	12 Months Ended
Note 15 - Equity-based Compensation (Tables)	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2022 132 $ 37.99 7.5 $ 69 Options granted 42 1.67 Restricted stock units granted 5 — Options exercised — — Restricted stock units vested (5 ) — Options forfeited/cancelled (19 ) 62.39 Restricted stock units cancelled (30 ) — Outstanding at December 31, 2023 125 31.15 7.3 1 Vested and expected to vest at December 31, 2023 119 32.40 7.3 1 Vested and exercisable at December 31, 2023 63 56.85 5.7 —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	For the Years Ended December 31, 2023 2022 Research and development $ 21 $ 20 Sales and marketing 96 52 General and administrative 174 148 Total stock-based compensation expense $ 291 $ 220
Employees and Directors [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Years Ended December 31, Assumptions 2023 2022 Expected price volatility 154 % 158 % Expected term (in years) 6.66 6.45 Risk-free interest rate 3.57 % 2.36 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.29 $ 9.22

Note 16 - Distribution Agreem_2

Note 16 - Distribution Agreements (Tables)	12 Months Ended
Note 16 - Distribution Agreements (Tables)	Dec. 31, 2023
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807 Provision related to sales made in: Current period 716 321 106 1,143 Payments and customer credits issued (1,476 ) (362 ) (166 ) (2,004 ) Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2021 $ 1,150 $ 83 $ 56 $ 1,289 Provision related to sales made in: Current period 1,865 65 448 2,378 Payments and customer credits issued (1,342 ) (95 ) (423 ) (1,860 ) Balance at December 31, 2022 $ 1,673 $ 53 $ 81 $ 1,807

Note 18 - Income Taxes (Tables)

Note 18 - Income Taxes (Tables)	12 Months Ended
Note 18 - Income Taxes (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	For the Years Ended December 31, 2023 2022 United States $ (9,640 ) $ (10,608 ) International — — $ (9,640 ) $ (10,608 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the Years Ended December 31, 2023 2022 Current Federal $ — $ — State — — Other — — Total current tax expense $ — $ — Deferred Federal — — State — — Other — — Total deferred tax expense $ — $ — Income tax provision $ — $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	For the Years Ended December 31, 2023 2022 Deferred tax assets: Net operating losses $ 36,943 $ 35,234 Acquisition assets 2,257 — Stock options 665 750 Research and development credits 641 641 Accruals 477 464 Operating lease liabilities 368 472 Property and equipment 28 13 Other deferred tax assets 6 331 Total deferred tax assets 41,385 37,905 Deferred tax liabilities: Operating lease right-of-use assets (337 ) (472 ) Total deferred tax liabilities (337 ) (472 ) Valuation allowance (41,048 ) (37,433 ) Net deferred taxes $ — $ —
Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]	Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 44,443 Does Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 Beginning in 2024 Net operating losses, state $ 117,375 Beginning in 2028 Tax credits, federal $ 542 Beginning in 2031 Tax credits, state $ 125 Indefinite
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	For the Years Ended December 31, 2023 2022 Unrecognized benefit - beginning of period $ 974 $ 974 Change during the period — — Unrecognized benefit - end of period $ 974 $ 974
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the Years Ended December 31, 2023 2022 Statutory rate 21.0 % 21.0 % State tax 4.5 % 7.9 % Change in valuation allowance (19.5 %) (48.0 %) Warrant/equity expenses (3.7 %) 20.2 % Stock-based compensation expense (1.4 %) (4.2 %) Impairment of assets (0.9 %) — % Other (0.1 %) (0.1 %) Change in value of earnout — % 3.2 % Total 0.0 % 0.0 %

Note 19 - Related Party Trans_2

Note 19 - Related Party Transactions (Tables)	12 Months Ended
Note 19 - Related Party Transactions (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	For the Years Ended December 31, 2023 2022 Chongqing Pioneer Pharma Holdings Limited: Revenue $ 1,377 $ 976 Cost of goods sold 1,225 954

Note 20 - Segment Reporting (Ta

Note 20 - Segment Reporting (Tables)	12 Months Ended
Note 20 - Segment Reporting (Tables)	Dec. 31, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Year Ended Ended December 31, Percentage December 31, Percentage 2023 of Total 2022 of Total Eyecare & Wound Care $ 11,174 76 % $ 10,239 71 % Skincare 3,552 24 % 4,165 29 % Total sales, net $ 14,726 100 % $ 14,404 100 % Eyecare & Wound Care $ 3,650 48 % $ 5,645 39 % Skincare 3,946 52 % 8,772 61 % Total operating loss $ 7,596 100 % $ 14,417 100 %

Note 1 - Organization (Details

Note 1 - Organization (Details Textual)		12 Months Ended
Note 1 - Organization (Details Textual)	Nov. 15, 2022	Dec. 31, 2023
Number of Reportable Segments		2
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	35

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands		12 Months Ended
	Jan. 01, 2022	Dec. 31, 2023	Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss		$ 3	$ 19
Inventory Valuation Reserves		627	499
Goodwill and Intangible Asset Impairment		2,593	6,737
Gain (Loss) on Fair Value Adjustment of Contingent Consideration		600
Impairment, Long-Lived Asset, Held-for-Use		$ 2	66
Payment for Product Supply Period (Day)		30 days
Advertising Expense		$ 1,100	2,000
Goodwill and Intangible Asset Impairment [Member]
Impairment of Intangible Assets, Finite-Lived		1,000	1,600
Operating Lease, Impairment Loss		100
Trade Names [Member] \| Goodwill and Intangible Asset Impairment [Member]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	$ 1,000	1,100
DERMAdoctor [Member]
Goodwill and Intangible Asset Impairment		300	4,200
DERMAdoctor [Member] \| General and Administrative Expense [Member]
Impairment, Long-Lived Asset, Held-for-Use		$ 2	$ 66
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years
Computer Equipment and Software [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Computer Equipment and Software [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years
Revenue from Contract with Customer Benchmark [Member] \| Distributor Concentration Risk [Member] \| Avenova Spray [Member]
Concentration Risk, Percentage		67%	73%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 3,130	$ 5,362
Restricted cash included in other assets	476	484
Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows	$ 3,606	$ 5,846	$ 7,979

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total sales, net	$ 14,726	$ 14,404
Avenova Spray [Member]
Total sales, net	7,805	7,651
DERMAdoctor [Member]
Total sales, net	3,552	4,155
NeutroPhase [Member]
Total sales, net	1,377	976
Other Products [member]
Total sales, net	1,953	1,592
Total Product Revenue [Member]
Total sales, net	14,687	14,374
Product and Service, Other [Member]
Total sales, net	$ 39	$ 30

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Chongqing Pioneer Pharma Holdings Limited [Member]
Accounts receivable, concentration risk	32%	11%
Accounts receivable, concentration risk	32%	11%
Major U.S. Retailer A [Member]
Accounts receivable, concentration risk	21%
Accounts receivable, concentration risk	21%
Distributor B [Member]
Accounts receivable, concentration risk	12%	30%
Accounts receivable, concentration risk	12%	30%
Major U.S. Retailer B [Member]
Accounts receivable, concentration risk		15%
Accounts receivable, concentration risk		15%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Anti-dilutive securities (in shares)	34,323,344	4,642,803
Series B Preferred Stock [Member]
Anti-dilutive securities (in shares)	22,428,000	1,847,580
Series C Preferred Stock [Member]
Anti-dilutive securities (in shares)	4,388,000	357,750
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	124,897	131,954
Warrant [Member]
Anti-dilutive securities (in shares)	7,382,447	2,305,519

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Restricted cash held as a certificate of deposit	$ 476	$ 484
Warrant liability	334
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	476	484
Warrant liability	0
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit	0	0
Warrant liability	0
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit	0	$ 0
Warrant liability	$ 334

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)		12 Months Ended
	Dec. 21, 2023 USD ($)	Dec. 31, 2023 USD ($) yr	Dec. 31, 2022 USD ($)
Non-cash gain on changes in fair value of warrant liability		$ (272,000)	$ (5,446,000)
May 2023 Warrants [Member]
Non-cash gain on changes in fair value of warrant liability	$ 200,000
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member]
Total Value		$ 9,600,000
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		18.55
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		13.18
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.87
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0131
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Reporting Date, December 31, 2021 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		6
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member]
Total Value		$ 7,500,000
Non-cash gain on changes in fair value of warrant liability		$ 2,100,000
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		18.55
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		10.5
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.91
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0165
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Stockholder approval, January 31, 2022 [Member] \| The November 2021 Warrants [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		6
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member]
Total Value		$ 5,200,000
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		6.3
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		6.29
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.796
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0358
Amendment, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		3.4
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member]
Total Value		$ 1,900,000
Non-cash gain on changes in fair value of warrant liability		$ 3,400,000
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		2.8
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.795
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		6.3
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0393
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		3.2
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0415
Stockholder approval, November 10, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5.8
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member]
Total Value		$ 1,600,000
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.3
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.72
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.801
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.036
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		2.1
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0404
Issuance, May 1, 2023 [Member] \| May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5.1
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member]
Total value, embedded		$ 200,000
Gain, embedded derivative		$ 40,000
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative		1.3
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Share Price [Member]
Measurement input, embedded derivative		0.75
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative		0.769
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative		0.0541
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative		0
Stockholder Approval, June 9, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Expected Term [Member]
Measurement input, embedded derivative \| yr		0.7
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member]
Total Value		$ 1,400,000
Non-cash gain on changes in fair value of warrant liability		$ 200,000
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.3
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.68
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.776
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0392
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		2
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0459
Stockholder Approval, June 9, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member]
Total Value		$ 400,000
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		0.25
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.23
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0388
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Issuance, December 21, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5.5
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member]
Total Value		$ 300,000
Non-cash gain on changes in fair value of warrant liability		$ 56,000
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		0.25
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.2
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0385
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Reporting Date, December 31, 2023 [Member] \| The December 2023 Warrants [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5.5
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member]
Total Value		$ 6,900,000
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		14
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		6.29
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.796
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0364
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Pre-amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		1.3
Pre-amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0343
Pre-amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		0.7
Pre-amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0358
Pre-amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		5.4
Pre-amendment, September 9, 2022 [Member] \| The July 2020 Warrants [Member] \| Minimum [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member]
Total Value		$ 12,500,000
Deemed dividend		$ 5,700,000
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		6.3
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		6.29
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.796
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0364
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Post amendment, September 9, 2022 [Member] \| Series B Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		1.3
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member]
Total Value		$ 5,200,000
Non-cash gain on changes in fair value of warrant liability		$ 1,900,000
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0358
Post amendment, September 9, 2022 [Member] \| The July 2020 and November 2021 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		6
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value		$ 9,600,000
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		6.3
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.72
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.801
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0491
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Pre-amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		0.8
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member]
Total Value		$ 300,000
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		6.3
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.72
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.801
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0359
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		1.1
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0473
Pre-amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		5.6
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value		$ 11,600,000
Deemed dividend		$ 2,000,000
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.3
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.72
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.801
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0491
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Post amendment, April 27, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		0.8
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member]
Total Value		$ 500,000
Non-cash gain on changes in fair value of warrant liability		$ 200,000
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.5
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.72
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.801
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0473
Post amendment, April 27, 2023 [Member] \| July 2020, November 2021, September 2022 & November 2022 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		5.6
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value		$ 1,700,000
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.3
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.23
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0543
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Pre-amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		0.3
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member]
Total Value		$ 56,000
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		1.3
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.23
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0392
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		1.5
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0462
Pre-amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		4.5
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value		$ 6,800,000
Deemed dividend		$ 5,100,000
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		0.25
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.23
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0543
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Post amendment, December 21, 2023 [Member] \| Series B Preferred Stock and Series C Preferred Stock [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		0.3
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member]
Total Value		$ 200
Non-cash gain on changes in fair value of warrant liability		$ 100
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Exercise Price [Member]
Measurement Input		0.25
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Share Price [Member]
Measurement Input		0.23
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Price Volatility [Member]
Measurement Input		0.793
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement Input		0
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0392
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Minimum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		1.5
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0492
Post amendment, December 21, 2023 [Member] \| The May 2023 Warrants [Member] \| Maximum [Member] \| Measurement Input, Expected Term [Member]
Measurement Input		4.5
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member]
Total value, embedded		$ 200,000
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative		1.3
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Share Price [Member]
Measurement input, embedded derivative		0.72
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative		0.801
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative		0.0488
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative		0
Issuance, April 27, 2023 [Member] \| Convertible Debt [Member] \| Measurement Input, Expected Term [Member]
Measurement input, embedded derivative \| yr		0.8
Issuance, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Measurement Input		0.0343
Issuance, September 9, 2022 [Member] \| The July 2020, November 2021 and September 2022 Warrants [Member] \| Measurement Input, Expected Term [Member]
Measurement Input \| yr		6

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Prepaid dues and subscriptions	$ 85	$ 43
Prepaid taxes	83	1
Prepaid inventory	73	211
Prepaid insurance	66	146
Other	81	159
Total prepaid expenses and other current assets	$ 388	$ 560

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Raw materials and supplies	$ 1,027	$ 1,273
Finished goods	2,477	2,663
Less: Reserve for excess and obsolete inventory	(627)	(499)
Total inventory, net	$ 2,877	$ 3,437

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation, Depletion and Amortization	$ 51	$ 120
Impairment of Long-Lived Assets to be Disposed of		68
Impairment, Long-Lived Asset, Held-for-Use	2	66
General and Administrative Expense [Member] \| DERMAdoctor [Member]
Impairment, Long-Lived Asset, Held-for-Use	$ 2	$ 66

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property and equipment, at cost	$ 760	$ 741
Less: Accumulated depreciation	(673)	(622)
Total property and equipment, net	87	119
Office and Laboratory Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	431	412
Leasehold Improvements [Member]
Property and equipment, at cost	$ 152	$ 152

Note 7 - Goodwill (Details Text

Note 7 - Goodwill (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill, Impairment Loss	$ 348	$ 4,180
DERMAdoctor [Member] \| Goodwill and Intangible Asset Impairment [Member]
Goodwill, Impairment Loss	$ 300	$ 4,200

Note 7 - Goodwill - Goodwill (D

Note 7 - Goodwill - Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 348	$ 4,528
Goodwill impairment	348	4,180
Balance	$ 0	$ 348

Note 8 - Other Intangible Ass_3

Note 8 - Other Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Impairment of Intangible Assets (Excluding Goodwill)	$ 2,100	$ 2,600
Amortization of Intangible Assets	$ 152	$ 363

Note 8 - Other Intangible Ass_4

Note 8 - Other Intangible Assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Trade names, gross	$ 2,080	$ 2,080
Total other intangible assets, impairment	(4,685)	(2,557)
Trade names, net	0	1,110
Amortizable intangible assets, accumulated amortization	(575)	(423)
Total other intangible assets	5,260	5,260
Total other intangible assets, net	0	2,280
Customer Relationships [Member]
Total other intangible assets, impairment	(230)	(172)
Amortizable intangible assets, gross	290	290
Amortizable intangible assets, accumulated amortization	(60)	(48)
Amortizable intangible assets, net	0	70
Trade Secrets [Member]
Total other intangible assets, impairment	(2,375)	(1,415)
Amortizable intangible assets, gross	2,890	2,890
Amortizable intangible assets, accumulated amortization	(515)	(375)
Amortizable intangible assets, net	0	1,100
Trade Names [Member]
Total other intangible assets, impairment	$ (2,080)	$ (970)

Note 9 - Accrued Liabilities -

Note 9 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Contract liabilities (see Note 16)	$ 946	$ 1,807
Employee payroll and benefits	341	261
Marketing costs	14	104
Inventory purchases	17	101
Other	198	451
Total accrued liabilities	$ 1,516	$ 2,724

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies (Details Textual)	Dec. 31, 2023 ft²
Riverside, Missouri [Member]
Area of Real Estate Property (Square Foot)	19,136

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease – expense	$ 525	$ 525
Operating lease – included in operating cash flow	$ 543	$ 540
Weighted-average remaining lease term (in years) (Year)	3 years 4 months 24 days	4 years 3 months 18 days
Weighted-average discount rate	5%	5%

Note 10 - Commitments and Con_5

Note 10 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024	$ 557
2025	439
2026	444
2027	290
Total future minimum lease payments	1,730
Less: Imputed interest	(127)
Total	1,603
Operating lease liability	495	$ 453
Operating lease liability- non-current	1,108	$ 1,588
Total	$ 1,603

Note 11 - Financing Activities

Note 11 - Financing Activities (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Dec. 21, 2023	May 01, 2023	Sep. 09, 2022	May 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2021
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.82	$ 7.7	$ 57.13
Proceeds from Warrant Exercises					$ 565	$ 1,703
Fair Value Adjustment of Warrants					$ (272)	$ (5,446)
Class of Warrant or Right, Exercised During Period (in shares)					2,528,848,000	(327,860,000)
Class of Warrant or Right, Issued During Period (in shares)					7,605,776,000	2,431,046,000
The 2023 Private Placement [Member]
Debt Issuance Costs, Net		$ 700
Other Expenses					$ 400
Proceeds From Debenture and Warrant Issuances, Net		3,000
Proceeds from Issuance of Warrants		1,600
Proceeds from Derivative Instrument, Financing Activities				$ 200
Proceeds from Convertible Debt		1,200
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Issuance Costs, Net		300			98
Debt Instrument, Face Amount		3,300
Fair Value Adjustment of Warrants		40
Debt Instrument, Unamortized Discount		300			$ 596
Original Issue Discount Senior Secured Convertible Debentures [Member] \| The 2023 Private Placement [Member]
Debt Instrument, Unamortized Discount		$ 300
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.3
Proceeds from Warrant Exercises					$ 200
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs					$ 100
Fair Value Adjustment of Warrants	$ 200
The 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25				$ 0.25
Proceeds from Warrant Exercises					$ 600
Debt Issuance Costs, Net					200
Other Expenses					$ 100
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.25
Proceeds from Warrant Exercises					$ 400
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 400
The Amended November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,071,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.5
Class of Warrant or Right, Exercised During Period (in shares)			267,860
Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		77,145	137,145
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Fair Value Adjustment of Warrants		$ 14,000	$ 400
Class of Warrant or Right, Exercised During Period (in shares)			60,000
The 2022 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			327,860
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Proceeds from Warrant Exercises			$ 2,100
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs			$ 300
Class of Warrant or Right, Issued During Period (in shares)			327,860
Payments of Stock Issuance Costs			$ 500
Payments of Stock Issuance Costs Allocated to Warrants			200
The November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		535,716						1,071,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					6.3			$ 18.55
Proceeds from Warrant Exercises			700
The September 2022 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 6.3
Proceeds from Warrant Exercises			$ 1,400

Note 12 - Convertible Notes (De

Note 12 - Convertible Notes (Details Textual) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	May 01, 2023 USD ($)	Apr. 27, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 09, 2023 USD ($)
Repayments of Convertible Debt				$ 1,474	$ 0
Fair Value Adjustment of Warrants				(272)	$ (5,446)
The 2023 Private Placement [Member]
Proceeds from Convertible Debt	$ 1,200
Debt Issuance Costs, Net	700
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Instrument, Face Amount	3,300
Debt Instrument, Unamortized Discount	300		$ 596	$ 596
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 1.3
Debt Instrument, Convertible, Number of Equity Instruments		2,538,464		1,454,021
Debt Instrument, Increase (Decrease), Net		$ (183)
Debt Instrument, Redemption Price, Amount Per Month		$ 193				$ 193
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90%
Debt Instrument, Convertible, Threshold Trading Days		10
Debt Instrument, Redemption Price, Percentage		20%
Repayments of Convertible Debt			126
Debt Instrument, Default, Interest Rate		18%
Embedded Derivative, Fair Value		$ 209					$ 169
Fair Value Adjustment of Warrants	40
Debt Issuance Costs, Net	300		$ 98	$ 98
Debt Instrument, Interest Rate, Effective Percentage			173%	173%
Amortization of Debt Issuance Costs and Discounts				$ 1,700
Original Issue Discount Senior Secured Convertible Debentures [Member] \| The 2023 Private Placement [Member]
Debt Instrument, Unamortized Discount	$ 300
Original Issue Discount Senior Secured Convertible Debentures [Member] \| Measurement Input, Redemption in Stock [Member]
Debt Instrument, Redemption Price, Amount Per Month		$ 193

Note 12 - Convertible Note - Co

Note 12 - Convertible Note - Convertible Notes (Details) - USD ($) $ in Thousands	Dec. 31, 2023	May 01, 2023	Dec. 31, 2022
Total Secured Convertible Notes, net	$ 1,137		$ 0
Original Issue Discount Senior Secured Convertible Debentures [Member]
Principal amount	1,831
Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants	(596)	$ (300)
Unamortized debt issuance costs	(98)	$ (300)
Total Secured Convertible Notes, net	$ 1,137

Note 12 - Convertible Note - _2

Note 12 - Convertible Note - Contractual Maturity (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Original Issue Discount Senior Secured Convertible Debentures [Member]
2024, convertible debt	$ 1,831

Note 13 - Common Stock Warran_3

Note 13 - Common Stock Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Dec. 21, 2023	May 01, 2023	Sep. 09, 2022	Dec. 31, 2023	Dec. 31, 2022	Nov. 10, 2022	Dec. 31, 2021	Nov. 30, 2021	Sep. 09, 2020	Jul. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.82	$ 7.7		$ 57.13
Class of Warrant or Right, Exercised During Period (in shares)				2,528,848,000	(327,860,000)
Fair Value Adjustment of Warrants				$ (272)	$ (5,446)
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.25
The May 2023 B-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.3		0.25
Class of Warrant or Right, Exercised During Period (in shares)	634,616
The May 2023 B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.3		$ 0.25
Class of Warrant or Right, Exercised During Period (in shares)	1,894,232
The 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25			$ 0.25
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.3
Fair Value Adjustment of Warrants	$ 200
The November 2022 A-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		436,510				515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3		$ 6.3
The November 2022 A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		436,510				515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3		$ 6.3
The November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3
The Amended November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 100
The 2022 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			327,860
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
September 2022 Warrants Exercisable for 1.50 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		238,574
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 46
The November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		535,716						1,071,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3				$ 18.55
Amended November 2021 Warrants Exercisable for 6.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Class of Warrant or Right, Exercised During Period (in shares)			267,860
Fair Value Adjustment of Warrants			$ 1,500
Amended November 2021 Warrants Exercisable for 1.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 100
The July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									137,145	197,105
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 57.75						$ 57.75
Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		77,145	137,145
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Class of Warrant or Right, Exercised During Period (in shares)			60,000
Fair Value Adjustment of Warrants		$ 14,000	$ 400
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 400

Note 13 - Common Stock Warran_4

Note 13 - Common Stock Warrants - Outstanding Warrants (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding warrants (in shares)	2,305,519	202,333
Outstanding warrants, weighted-average exercise price (in dollars per share)	$ 7.7	$ 57.13
Warrants granted (in shares)	7,605,776	2,431,046
Warrants granted, weighted average exercise price (in dollars per share)	$ 0.95	$ 11.7
Warrants exercised (in shares)	2,528,848	(327,860)
Warrants exercised, weighted-average exercise price (in dollars per share)	$ 0.25	$ 6.3
Warrants expired (in shares)	0	0
Warrants expired, weighted average exercise price (in dollars per share)	$ 0	$ 0
Warrants exercised (in shares)	(2,528,848)	327,860
Outstanding warrants (in shares)	7,382,447	2,305,519
Outstanding warrants, weighted-average exercise price (in dollars per share)	$ 1.82	$ 7.7

Note 13 - Common Stock Warran_5

Note 13 - Common Stock Warrants - Warrants Outstanding (Details) - $ / shares shares in Thousands	Dec. 31, 2023	May 01, 2023	Dec. 31, 2022	Nov. 10, 2022	Dec. 31, 2021	Nov. 30, 2021	Jul. 31, 2020
Exercise price (in dollars per share)	$ 1.82		$ 7.7		$ 57.13
Warrants outstanding (in shares)	7,382,447		2,305,519		202,333
The 2019 Ladenburg Warrants [Member]
Exercise price (in dollars per share)	$ 34.65
Expiration date	Aug. 08, 2024
Warrants outstanding (in shares)	4,799
The July 2020 Warrants [Member]
Exercise price (in dollars per share)	$ 57.75						$ 57.75
Expiration date	Jan. 22, 2026
Warrants outstanding (in shares)	59,960
The Amended July 2020 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Jan. 22, 2026
Warrants outstanding (in shares)	77,145
TLF Bio Innovation 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 23.51
Expiration date	Jan. 15, 2026
Warrants outstanding (in shares)	429
The November 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3					$ 18.55
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	267,858
The Amended November 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	535,716
The September 2022 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	89,286
The Amended September 2022 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	238,574
The November 2022 A-1 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3			$ 6.3
Expiration date	Nov. 20, 2028
Warrants outstanding (in shares)	79,366
The Amended November 2022 A-1 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Nov. 20, 2028
Warrants outstanding (in shares)	436,510
The November 2022 A-2 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3			$ 6.3
Expiration date	May 20, 2024
Warrants outstanding (in shares)	79,366
The Amended November 2022 A-2 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	May 20, 2024
Warrants outstanding (in shares)	436,510
The May 2023 B-1 Warrants [Member]
Exercise price (in dollars per share)	$ 0.25	$ 1.3
Expiration date	Jun. 09, 2028
Warrants outstanding (in shares)	1,903,848
The May 2023 B-2 Warrants [Member]
Exercise price (in dollars per share)	$ 0.25	$ 1.3
Expiration date	Jun. 09, 2025
Warrants outstanding (in shares)	644,232
The December 2023 Warrants [Member]
Exercise price (in dollars per share)	$ 0.25
Expiration date	Jun. 21, 2029
Warrants outstanding (in shares)	2,528,848

Note 13 - Common Stock Warran_6

Note 13 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
The 2022 Warrant Reprice Transaction [Member]
Fair value of warrant liabilities recognized		$ 5,241,000
Warrant Liability [Member]
Fair value of warrant liability, balance	$ 0	9,558,000
Fair value of warrant liability, balance	334,000	0
Warrant Liability [Member] \| The November 2021 Warrants [Member]
Decrease in fair value of warrants		(2,056,000)
Reclassification of Warrants		(7,502,000)
Reclassification of Warrants		7,502,000
Warrant Liability [Member] \| The 2022 Warrant Reprice Transaction [Member]
Decrease in fair value of warrants		(3,390,000)
Reclassification of Warrants		1,851,000
Reclassification of Warrants		$ (1,851,000)
Warrant Liability [Member] \| May 2023 Warrants [Member]
Decrease in fair value of warrants	(216,000)
Reclassification of Warrants	1,360
Fair value of warrant liabilities recognized	1,576,000
Reclassification of Warrants	(1,360)
Warrant Liability [Member] \| The December 2023 Warrants [Member]
Decrease in fair value of warrants	(56,000)
Fair value of warrant liabilities recognized	$ 390

Note 14 - Stockholders' Equity

Note 14 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions	Jan. 09, 2024 $ / shares shares	Dec. 21, 2023 USD ($) $ / shares	Apr. 27, 2023 USD ($) $ / shares	Nov. 15, 2022	Sep. 09, 2022 USD ($) $ / shares shares	Oct. 29, 2021 shares	Mar. 24, 2024 $ / shares shares	Jan. 29, 2024 $ / shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Common Stock, Shares Authorized (in shares)									150,000,000	150,000,000
Preferred Stock, Shares Authorized (in shares)									5,000,000
Preferred Stock, Convertible, Shares Issuable (in shares)									1,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				35
Subsequent Event [Member] \| Conversion of Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)	15,000
May 2023 Warrants [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 1.3
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									5,000,000	5,000,000
Preferred Stock, Shares Outstanding (in shares)									6,000	12,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 6.3
Preferred Stock, Change in Conversion Price, Income Statement Impact \| $		$ 4.5			$ 5.7
Series B Preferred Stock [Member] \| Subsequent Event [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares	$ 0.25							$ 0.25
Series B Preferred Stock [Member] \| Subsequent Event [Member] \| Minimum [Member]
Preferred Stock, Convertible, Conversion Ratio	75
Series B Preferred Stock [Member] \| Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 1.3			$ 14
Series B Preferred Stock [Member] \| Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 0.25			$ 6.3
Series B Preferred Stock [Member] \| The 2021 Private Placement Program [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)									22,428,000	1,847,580
Stock Issued During Period, Shares, New Issues (in shares)						15,000
Preferred Stock, Shares Outstanding (in shares)									5,607	11,620
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares									$ 0.25	$ 6.3
Series B Preferred Stock [Member] \| The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact \| $			$ 1.8
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding (in shares)									1,000	2,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 6.3						$ 0.25
Preferred Stock, Change in Conversion Price, Income Statement Impact \| $		$ 0.5
Preferred Stock, Convertible, Conversion Ratio									4,000
Series C Preferred Stock [Member] \| Subsequent Event [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)							2,787,841
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares							$ 0.14
Preferred Stock, Convertible, Conversion Ratio							7,143
Series C Preferred Stock [Member] \| Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 1.3
Series C Preferred Stock [Member] \| Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares		$ 0.25
Series C Preferred Stock [Member] \| The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact \| $			$ 194
Series C Preferred Stock [Member] \| The 2022 Private Placement [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)									4,388,000	357,750
Stock Issued During Period, Shares, New Issues (in shares)					3,250
Preferred Stock, Shares Outstanding (in shares)									1,097	2,250
Preferred Stock, Convertible, Conversion Price (in dollars per share) \| $ / shares									$ 0.25	$ 6.3

Note 15 - Equity-based Compen_3

Note 15 - Equity-based Compensation (Details Textual) - USD ($)		1 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2017	Oct. 31, 2007	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 200,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 6 months 10 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				42,000
Share-Based Payment Arrangement, Expense				$ 291,000	$ 220,000
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				36,000	0
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				6,150	18,607
Share-Based Payment Arrangement, Expense				$ 300,000	$ 200,000
Restricted Stock [Member] \| Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				0
Share-Based Payment Arrangement, Expense				$ 40
Restricted Stock [Member] \| Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				5,148
The 2007 Omnibus Incentive Plan [Member] \| Maximum [Member] \| Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
The 2017 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		66,243
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock		4%		171,424%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	81,417
The 2017 Omnibus Incentive Plan [Member] \| Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum		10%
The 2017 Omnibus Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
The 2017 Omnibus Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The 2017 Omnibus Incentive Plan [Member] \| Maximum [Member] \| Incentive Stock Options (ISOs) [Member] \| Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
The 2017 Omnibus Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		100%
The 2017 Omnibus Incentive Plan [Member] \| Minimum [Member] \| Incentive Stock Options (ISOs) [Member] \| Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110%

Note 15 - Equity-based Compen_4

Note 15 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding awards (in shares)	132
Outstanding, weighted-average exercise price (in dollars per share)	$ 37.99
Outstanding, weighted-average remaining contractual life (Year)	7 years 3 months 18 days	7 years 6 months
Outstanding, aggregate intrinsic value	$ 1	$ 69
Options granted (in shares)	42
Options granted, weighted-average exercise price (in dollars per share)	$ 1.67
Options exercised (in shares)	0
Options forfeited/cancelled (in shares)	(19)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 62.39
Outstanding awards (in shares)	125	132
Outstanding, weighted-average exercise price (in dollars per share)	$ 31.15	$ 37.99
Vested and expected to vest (in shares)	119
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 32.4
Vested and expected to vest, weighted-average remaining contractual life (Year)	7 years 3 months 18 days
Vested and expected to vest, aggregate intrinsic value	$ 1
Vested and exercisable (in shares)	63
Exercisable, weighted-average exercise price (in dollars per share)	$ 56.85
Exercisable, weighted-average remaining contractual life (Year)	5 years 8 months 12 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	5
Restricted stock units vested (in shares)	(5)
Restricted stock units cancelled (in shares)	(30)

Note 15 - Equity-based Compen_5

Note 15 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Expected price volatility	154%	158%
Expected term (Year)	6 years 7 months 28 days	6 years 5 months 12 days
Risk-free interest rate	3.57%	2.36%
Dividend yield	0%	0%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 1.29	$ 9.22

Note 15 - Equity-based Compen_6

Note 15 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Stock-based compensation expense	$ 291	$ 220
Research and Development Expense [Member]
Stock-based compensation expense	21	20
Selling and Marketing Expense [Member]
Stock-based compensation expense	96	52
General and Administrative Expense [Member]
Stock-based compensation expense	$ 174	$ 148

Note 16 - Distribution Agreem_3

Note 16 - Distribution Agreements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer, Including Assessed Tax	$ 14,726	$ 14,404
Avenova Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	6,100	6,500
DERMAdoctor [Member]
Revenue from Contract with Customer, Including Assessed Tax	3,552	4,155
McKesson Corporation [Member] \| Avenova Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	100
McKesson Corporation [Member] \| Avenova Product [Member] \| Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability	700	1,600
Costco and Others [Member] \| DERMAdoctor [Member]
Revenue from Contract with Customer, Including Assessed Tax	700	900
Contract with Customer, Liability	$ 200	$ 200

Note 16 - Distribution Agreem_4

Note 16 - Distribution Agreements - Changes in Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Chargebacks, Discounts for Prompt, Payment, and Other [Member]
Balance	$ 1,673	$ 1,150
Current period	716	1,865
Payments and customer credits issued	(1,476)	(1,342)
Balance	913	1,673
Other Customer Fees [Member]
Balance	53	83
Current period	321	65
Payments and customer credits issued	(362)	(95)
Balance	12	53
Rebates [Member]
Balance	81	56
Current period	106	448
Payments and customer credits issued	(166)	(423)
Balance	21	81
Variable Consideration [Member]
Balance	1,807	1,289
Current period	1,143	2,378
Payments and customer credits issued	(2,004)	(1,860)
Balance	$ 946	$ 1,807

Note 17 - Employee Benefit Pl_2

Note 17 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
The 401K Plan Contribution Level One [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3%
The 401K Plan Contribution Level Two [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2%
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 122	$ 125

Note 18 - Income Taxes (Details

Note 18 - Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 3.6	$ 1.8
Domestic Tax Authority [Member]
Open Tax Year	2019 2020 2021 2022
State and Local Jurisdiction [Member] \| California Franchise Tax Board [Member]
Open Tax Year	2018 2019 2020 2021 2022

Note 18 - Income Taxes - Loss B

Note 18 - Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
United States	$ (9,640)	$ (10,608)
International	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ (9,640)	$ (10,608)

Note 18 - Income Taxes - Federa

Note 18 - Income Taxes - Federal and State Income Tax Provisions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Current
Federal	$ 0
State	0
Other	0
Total current tax expense	0
Deferred
Federal	0
State	0
Other	0
Total deferred tax expense	0
Income tax provision	$ 0

Note 18 - Income Taxes - Summar

Note 18 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Net operating losses	$ 36,943	$ 35,234
Acquisition assets	2,257	0
Stock options	665	750
Research and development credits	641	641
Accruals	477	464
Operating lease liabilities	368	472
Property and equipment	28	13
Other deferred tax assets	6	331
Total deferred tax assets	41,385	37,905
Deferred tax liabilities:
Operating lease right-of-use assets	(337)	(472)
Total deferred tax liabilities	(337)	(472)
Valuation allowance	(41,048)	(37,433)
Net deferred taxes	$ 0	$ 0

Note 18 - Income Taxes - Summ_2

Note 18 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Domestic Tax Authority [Member] \| Internal Revenue Service (IRS) [Member] \| Not Subject to Expiration [Member]
Net operating losses	$ 44,443
Domestic Tax Authority [Member] \| Internal Revenue Service (IRS) [Member] \| Expiration Years 2024 - 2037 [Member]
Net operating losses	94,886
Domestic Tax Authority [Member] \| Internal Revenue Service (IRS) [Member] \| Expiration Year 2031 [Member]
Tax credits	542
State and Local Jurisdiction [Member] \| Not Subject to Expiration [Member]
Tax credits	125
State and Local Jurisdiction [Member] \| Expiration Years 2028 - 2037 [Member]
Net operating losses	$ 117,375

Note 18 - Income Taxes - Unreco

Note 18 - Income Taxes - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Unrecognized benefit - beginning of period	$ 974	$ 974
Change during the period	0	0
Unrecognized benefit - end of period	$ 974	$ 974

Note 18 - Income Taxes - Effect

Note 18 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statutory rate	21%	21%
State tax	4.50%	7.90%
Change in valuation allowance	(19.50%)	(48.00%)
Warrant/equity expenses	(3.70%)	20.20%
Stock-based compensation expense	1.40%	4.20%
Impairment of assets	(0.90%)	0%
Other	0.10%	0.10%
Change in value of earnout	0%	3.20%
Total	0%	0%

Note 19 - Related Party Trans_3

Note 19 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Related Party [Member]
Accounts Receivable, before Allowance for Credit Loss	$ 0.2	$ 0.2

Note 19 - Related Party Trans_4

Note 19 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cost of goods sold	$ 6,831	$ 6,623
Related Party [Member]
Revenue	1,377	976
Cost of goods sold	$ 1,225	$ 954

Note 20 - Segment Reporting (De

Note 20 - Segment Reporting (Details Textual)	12 Months Ended
Note 20 - Segment Reporting (Details Textual)	Dec. 31, 2023
Number of Reportable Segments	2

Note 20 - Segment Reporting - F

Note 20 - Segment Reporting - Financial Information by Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer, Including Assessed Tax	$ 14,726	$ 14,404
Total sales, percentage	100%	100%
Operating loss	$ 7,596	$ 14,417
Operating loss, percentage	100%	100%
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 14,687	$ 14,374
Optical and Wound Care [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 11,174	$ 10,239
Total sales, percentage	76%	71%
Operating loss	$ 3,650	$ 5,645
Operating loss, percentage	48%	39%
Skin Care [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 3,552	$ 4,165
Operating loss	$ 3,946	$ 8,772
Skin Care [Member] \| Product [Member]
Total sales, percentage	24%	29%
Operating loss, percentage	52%	61%

Note 21 - Subsequent Event (Det

Note 21 - Subsequent Event (Details Textual)			12 Months Ended
Note 21 - Subsequent Event (Details Textual)	Mar. 24, 2024 USD ($) $ / shares shares	Oct. 29, 2021 shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 14, 2024 USD ($)	Jan. 29, 2024 $ / shares	Jan. 09, 2024 $ / shares	Apr. 27, 2023 $ / shares	Dec. 31, 2021 $ / shares
Goodwill and Intangible Asset Impairment \| $			$ 2,593,000	$ 6,737,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.82	$ 7.7					$ 57.13
Preferred Stock, Convertible, Shares Issuable (in shares) \| shares			1,000
DERMAdoctor [Member]
Goodwill and Intangible Asset Impairment \| $			$ 2,600,000	$ 6,700,000
Subsequent Event [Member] \| Unsecured Convertible Notes [Member]
Debt Instrument, Face Amount \| $	$ 525,000
Debt Instrument, Convertible, Number of Equity Instruments	3,750,000
Subsequent Event [Member] \| Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.14
Subsequent Event [Member] \| DERMAdoctor [Member] \| New Age Investments [Member]
Disposal Group, Including Discontinued Operation, Consideration \| $					$ 1,100,000
Subsequent Event [Member] \| DERMAdoctor [Member] \| New Age Investments [Member]
Investment Owned, Net Assets, Percentage					100%
Series B Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)								$ 6.3
Series B Preferred Stock [Member] \| Subsequent Event [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)						$ 0.25	$ 0.25
Series B Preferred Stock [Member] \| The 2021 Private Placement Program [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares		15,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 0.25	$ 6.3
Preferred Stock, Convertible, Shares Issuable (in shares) \| shares			22,428,000	1,847,580
Series C Preferred Stock [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 0.25					$ 6.3
Preferred Stock, Convertible, Conversion Ratio			4,000
Series C Preferred Stock [Member] \| Subsequent Event [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 0.14
Preferred Stock, Convertible, Conversion Ratio	7,143
Preferred Stock, Convertible, Shares Issuable (in shares) \| shares	2,787,841